Oral bisphosphonates for the prevention of androgen deprivation therapy-associated bone loss - Preliminary findings.


4749 Background: Androgen deprivation therapy (ADT) is a widely administered treatment for prostate cancer. However, ADT causes accelerated bone loss. Annual bone loss on ADT ranges between 2.0 to 10.0 percent per year. Intravenous bisphosphonates (pamidronate, zolendronate) have been shown to prevent ADT-related bone loss in randomized phase III trials… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.